Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC1779 in Thrombotic Microangiopathy: Randomized Double-blind Placebo-controlled Phase 2 Study
2008-001872-54Phase 2Terminated
- Sponsor
- Archemix Corp.
- Start
- Oct 2008
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thrombotic microangiopathies (TMA) and coagulation defects comparing ARC1779 Injection with Placebo Injection (2 arms). Primary endpoint: Primary composite clinical and biomarker outcome. Started Oct 2008; status: terminated.
02
Drugs
egaptivon pegol
03
Conditions
thrombotic microangiopathies (TMA)coagulation defects
Beyond the preview
Go deeper on 2008-001872-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001872-54.